In the modern pharmaceutical industry, pharmaceutical excipients are no longer simply fillers, as they were traditionally understood. Instead, they are key factors that directly impact drug stability, safety, and efficacy.
With the deepening integration of the global pharmaceutical industry chain, both pharmaceutical manufacturers and API suppliers have placed higher demands on the quality and compliance of pharmaceutical excipients.
Pharmaceutical excipients refer to all ingredients in pharmaceutical formulations other than the active ingredient (API). While they typically lack pharmacological activity, they play a vital role in drug development and production. For example, they can:
Category | Function | Typical Examples |
Fillers | Increase the volume of tablets or capsules to facilitate preparation molding | Lactose, microcrystalline cellulose |
Binders | Enhance the bonding strength between powders and improve tablet hardness | Hydroxypropyl methylcellulose (HPMC), povidone (PVP) |
Disintegrants | Helps tablets disperse quickly in the gastrointestinal tract and improves drug absorption | Croscarmellose sodium, cross-linked polyvinylpyrrolidone |
Lubricant | Reduce friction during production and prevent sticking | magnesium stearate |
Coating Materials | Improve drug appearance, mask bitter taste, and control release | Hydroxypropyl methylcellulose, enteric material |
In drug development, the choice of excipients often directly impacts the success of the final product:
Many people believe that excipients are only a consideration for pharmaceutical manufacturers, but this is not the case. As API suppliers, we also need a deep understanding of the characteristics of excipients:
Pharmaceutical excipients are rapidly evolving towards functionalization and intelligentization:
Through years of API R&D and production, we have come to realize that the perfect synergy between high-quality excipients and APIs is crucial for safe and effective pharmaceuticals. Pharmaceutical excipients have evolved from a supporting role to a strategic resource in the pharmaceutical industry.
For API and intermediate manufacturers, understanding the role of excipients in drug development and production not only facilitates deeper collaboration with downstream companies but also enhances competitiveness within the global supply chain.
Tianming Pharmaceutical Group not only focuses on providing high-quality APIs and intermediates, but also consistently monitors the latest developments in excipient technology to ensure our products meet the demands of various formulation processes.
We believe that only by deeply understanding the characteristics of excipients can we provide customers with more comprehensive technical support and jointly advance the development of the pharmaceutical industry. If you require professional advice on API or intermediate selection, please feel free to contact us.
Email: sunqian0123@gmail.com
Brigatinib manufacturer guide: Takeda (brand), Lonza (CDMO), and 72+ API vendors. Patent expiries: China 2026, US 2035. How to choose a reliable supplier for generic development.
This article summarizes 2025 latest research on ibrutinib’s long-term side effects, covering atrial fibrillation, bleeding, hypertension, infections and joint issues. It compares safety with newer BTK inhibitors and notes real-world treatment discontinuation risks.
Orforglipron vs retatrutide: oral small‑molecule GLP‑1 agonist vs triple‑hormone injectable. Phase 3 weight loss data, dosing schedules, side effects, regulatory status, and API manufacturing differences.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.